Scholarlink

Background <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is rising these days together with type 2 diabetes (T2DM) and obesity levels, which is the leading cause of chronic liver disease globally. Noninvasive markers can be used to detect patients with severe fibrosis and active MASH. FibroScan-AST (FAST) score is a simplified combination score that accounts for controlled attenuation parameter (CAP), liver stiffness (LSM), and serum aspartate aminotransferase (AST). It has been utilized to recognize individuals with fibrotic metabolic associated steatohepatitis (MASH). This study's goal is to figure out the metabolic features linked to a high FAST score.</p> Methods <p>a cross-sectional study that involved 385 participants with MASLD collected from Fibroscan Unit, steatosis detected by VCTE-CAP elastography. Then, the FAST score was estimated sorting patients according to their risk of developing fibrotic MASH as low (&lt; 0.35), medium (0.35–0.67), or high (&gt; 0.67).</p> Results <p>Linear regression identified the cumulative number of metabolic criteria as a significant predictor of higher FAST score (B = 0.107, <i>p</i> &lt; 0.001). In multivariable logistic regression, T2DM (OR = 3.62, 95% CI: 1.65–7.96, <i>p</i> = 0.001), hypertension (OR = 3.20, 95% CI: 1.45–7.07, <i>p</i> = 0.004), and dyslipidemia (OR = 3.28, 95% CI: 1.41–7.65, <i>p</i> = 0.006) were each independently associated with a high-risk FAST score. Age, sex, and body mass index were not significant predictors in the adjusted models.</p> Conclusions <p>calculating FAST score is crucial in identifying patients with fibrotic MASH. T2DM, Dyslipidemia, hypertension, and the presence of all cardiometabolic criteria have a substantially elevated risk of fibrosis and steatohepatitis.</p> Trial registration <p>NCT06867419</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic features’ effect on FibroScan-AST (FAST) score in Egyptian patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月9日

查看全文
  • Amal Mohammed Dwidar,
  • Ayat Ismail Ferra,
  • Amany Mohammed Dwidar,
  • Eslam Saber Esmail,
  • Rania Mamdouh Elkafoury

摘要

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is rising these days together with type 2 diabetes (T2DM) and obesity levels, which is the leading cause of chronic liver disease globally. Noninvasive markers can be used to detect patients with severe fibrosis and active MASH. FibroScan-AST (FAST) score is a simplified combination score that accounts for controlled attenuation parameter (CAP), liver stiffness (LSM), and serum aspartate aminotransferase (AST). It has been utilized to recognize individuals with fibrotic metabolic associated steatohepatitis (MASH). This study's goal is to figure out the metabolic features linked to a high FAST score.

Methods

a cross-sectional study that involved 385 participants with MASLD collected from Fibroscan Unit, steatosis detected by VCTE-CAP elastography. Then, the FAST score was estimated sorting patients according to their risk of developing fibrotic MASH as low (< 0.35), medium (0.35–0.67), or high (> 0.67).

Results

Linear regression identified the cumulative number of metabolic criteria as a significant predictor of higher FAST score (B = 0.107, p < 0.001). In multivariable logistic regression, T2DM (OR = 3.62, 95% CI: 1.65–7.96, p = 0.001), hypertension (OR = 3.20, 95% CI: 1.45–7.07, p = 0.004), and dyslipidemia (OR = 3.28, 95% CI: 1.41–7.65, p = 0.006) were each independently associated with a high-risk FAST score. Age, sex, and body mass index were not significant predictors in the adjusted models.

Conclusions

calculating FAST score is crucial in identifying patients with fibrotic MASH. T2DM, Dyslipidemia, hypertension, and the presence of all cardiometabolic criteria have a substantially elevated risk of fibrosis and steatohepatitis.

Trial registration

NCT06867419